Introduction The dramatic impact of COVID-19 on humans worldwide has initiated an
extraordinary search for effective treatment approaches. One of these is the administration of …

Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …

Background We have investigated the use of nebulized surfactant as a potential therapeutic
option for the patients with coronavirus disease 2019 (COVID-19)-associated acute …

Surfactant replacement might help recovery of low-compliance lung in severe COVID-19
pneumonia - Stefano Busani, Lorenzo Dall’Ara, Roberto Tonelli, Enrico Clini, Elena Munari …

Objectives SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2
(ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue …

Background: Severe pneumonia caused by coronavirus disease 2019 (COVID-19) is
characterized by inflammatory lung injury, progressive parenchymal stiffening and …

Patients with COVID-19 report severe respiratory symptoms consistent with ARDS. The
clinical presentation of ARDS in COVID-19 is often atypical, as patients with COVID-19 …

The COVID-19 pandemic has wielded an enormous pressure on global health care systems,
economics and politics. Ongoing vaccination campaigns effectively attenuate viral …

Lung alveolar type-II (AT-II) cells produce pulmonary surfactant (PS), consisting of proteins
and lipids. The lipids in PS are primarily responsible for reducing the air-fluid surface tension …

Corona virus SARS-CoV-2 has already spread around the whole world and is currently, with
no vaccine available yet, unstoppable. As per today, COVID-19 affects more than 3,000,000 …